FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159233376> ?p ?o ?g. }

• W2159233376 endingPage "1526" @default.
• W2159233376 startingPage "1519" @default.
• W2159233376 abstract "For gene therapy to be efficacious in the treatment of cancer, therapeutic transgenes must be limited in their expression to tumor cells and must be expressed at sufficiently high transcriptional levels. Moreover, the inadequacy of gene delivery must be overcome by induction of toxicity to neighboring nontargeted cells. Combining targeted radionuclide therapy with gene therapy using human telomerase promoters has shown promise in these respects, and the efficacy of this scheme has been assessed in vitro using transfectant mosaic tumor spheroids. To enable the evaluation of targeted radiotherapy combined with gene transfer in vivo, we have developed a transfectant mosaic xenograft (TMX) model.Human telomerase promoters were used to drive expression of the noradrenaline transporter (NAT) transgene in 2 human cell lines (UVW and EJ138). Promoter activity was assessed in xenografts in nude mice by determination of the uptake of the radiopharmaceutical (131)I-metaiodobenzylguanidine ((131)I-MIBG) and by measurement of tumor growth. The efficacy of (131)I-MIBG treatment was also assessed in TMXs to determine the delay in growth of tumors composed of various proportions of NAT-expressing cells-a likely clinical scenario after gene delivery in vivo.In terms of induction of the capacity for active uptake of (131)I-MIBG and the resultant inhibition of tumor growth in vivo, both telomerase promoters (hTR and hTERT) were similar in potency to the CMV (cytomegalovirus) promoter as controlling elements for the expression of the NAT transgene. In TMXs derived from UVW and EJ138 cells, (131)I-MIBG uptake was proportional to NAT gene expression (r(s) = 0.910, P < 0.001 for UVW; r(s) = 0.971, P < 0.001 for EJ138). Inhibition of the growth of these tumors correlated with the fraction of NAT-transfected cells (r(s) = 0.910, P < 0.001 for UVW; r(s) = 0.971, P < 0.001 for EJ138), and substantial tumor growth delay was observed when 5% of the xenograft was composed of NAT-positive cells.TMXs constitute a suitable model to measure the efficacy of cancer gene therapy strategies when <100% of the tumor mass can be targeted to express the therapeutic transgene." @default.
• W2159233376 created "2016-06-24" @default.
• W2159233376 creator A5009313090 @default.
• W2159233376 creator A5029520063 @default.
• W2159233376 creator A5060892126 @default.
• W2159233376 creator A5084998626 @default.
• W2159233376 date "2007-08-17" @default.
• W2159233376 modified "2023-09-27" @default.
• W2159233376 title "A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo" @default.
• W2159233376 cites W1894683927 @default.
• W2159233376 cites W1903945652 @default.
• W2159233376 cites W1925328674 @default.
• W2159233376 cites W1944076654 @default.
• W2159233376 cites W1964888123 @default.
• W2159233376 cites W1966496128 @default.
• W2159233376 cites W1967984930 @default.
• W2159233376 cites W1971700019 @default.
• W2159233376 cites W1990143951 @default.
• W2159233376 cites W2000971601 @default.
• W2159233376 cites W2005324578 @default.
• W2159233376 cites W2010956382 @default.
• W2159233376 cites W2014229406 @default.
• W2159233376 cites W2015060773 @default.
• W2159233376 cites W2026743099 @default.
• W2159233376 cites W2029224024 @default.
• W2159233376 cites W2046209641 @default.
• W2159233376 cites W2047551799 @default.
• W2159233376 cites W2053595697 @default.
• W2159233376 cites W2055079159 @default.
• W2159233376 cites W2072328760 @default.
• W2159233376 cites W2089804431 @default.
• W2159233376 cites W2091158789 @default.
• W2159233376 cites W2095883832 @default.
• W2159233376 cites W2102217966 @default.
• W2159233376 cites W2109445568 @default.
• W2159233376 cites W2113722366 @default.
• W2159233376 cites W2128625175 @default.
• W2159233376 cites W2132439768 @default.
• W2159233376 cites W2142214316 @default.
• W2159233376 cites W2142708250 @default.
• W2159233376 cites W2151230949 @default.
• W2159233376 cites W2163342565 @default.
• W2159233376 cites W2166522896 @default.
• W2159233376 cites W2335608256 @default.
• W2159233376 cites W2442893625 @default.
• W2159233376 cites W2472468540 @default.
• W2159233376 cites W2479044294 @default.
• W2159233376 doi "https://doi.org/10.2967/jnumed.107.042226" @default.
• W2159233376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17704246" @default.
• W2159233376 hasPublicationYear "2007" @default.
• W2159233376 type Work @default.
• W2159233376 sameAs 2159233376 @default.
• W2159233376 citedByCount "13" @default.
• W2159233376 countsByYear W21592333762013 @default.
• W2159233376 countsByYear W21592333762016 @default.
• W2159233376 countsByYear W21592333762017 @default.
• W2159233376 countsByYear W21592333762022 @default.
• W2159233376 crossrefType "journal-article" @default.
• W2159233376 hasAuthorship W2159233376A5009313090 @default.
• W2159233376 hasAuthorship W2159233376A5029520063 @default.
• W2159233376 hasAuthorship W2159233376A5060892126 @default.
• W2159233376 hasAuthorship W2159233376A5084998626 @default.
• W2159233376 hasBestOaLocation W21592333761 @default.
• W2159233376 hasConcept C101762097 @default.
• W2159233376 hasConcept C102230213 @default.
• W2159233376 hasConcept C104317684 @default.
• W2159233376 hasConcept C111599444 @default.
• W2159233376 hasConcept C125593758 @default.
• W2159233376 hasConcept C135983454 @default.
• W2159233376 hasConcept C150194340 @default.
• W2159233376 hasConcept C153911025 @default.
• W2159233376 hasConcept C207001950 @default.
• W2159233376 hasConcept C32470452 @default.
• W2159233376 hasConcept C40767141 @default.
• W2159233376 hasConcept C502942594 @default.
• W2159233376 hasConcept C54009773 @default.
• W2159233376 hasConcept C54355233 @default.
• W2159233376 hasConcept C86803240 @default.
• W2159233376 hasConcept C94581717 @default.
• W2159233376 hasConceptScore W2159233376C101762097 @default.
• W2159233376 hasConceptScore W2159233376C102230213 @default.
• W2159233376 hasConceptScore W2159233376C104317684 @default.
• W2159233376 hasConceptScore W2159233376C111599444 @default.
• W2159233376 hasConceptScore W2159233376C125593758 @default.
• W2159233376 hasConceptScore W2159233376C135983454 @default.
• W2159233376 hasConceptScore W2159233376C150194340 @default.
• W2159233376 hasConceptScore W2159233376C153911025 @default.
• W2159233376 hasConceptScore W2159233376C207001950 @default.
• W2159233376 hasConceptScore W2159233376C32470452 @default.
• W2159233376 hasConceptScore W2159233376C40767141 @default.
• W2159233376 hasConceptScore W2159233376C502942594 @default.
• W2159233376 hasConceptScore W2159233376C54009773 @default.
• W2159233376 hasConceptScore W2159233376C54355233 @default.
• W2159233376 hasConceptScore W2159233376C86803240 @default.
• W2159233376 hasConceptScore W2159233376C94581717 @default.
• W2159233376 hasIssue "9" @default.
• W2159233376 hasLocation W21592333761 @default.
• W2159233376 hasLocation W21592333762 @default.

• next